Skip to content
PoliticalRepoPoliticalRepo

Person

Official portrait of Rep. Bishop, Sanford D. [D-GA-2]

Rep. Bishop, Sanford D. [D-GA-2]

United States · Official source

Records

6,517 records where Rep. Bishop, Sanford D. [D-GA-2] is listed as a sponsor, author, or other actor. Search with topics and years

Amendment· HAMDTHAMDT 108 (114th)open

An amendment to decrease and then increase funding for military construction, army, by $1; to increase funding for VHA medical services by $154,643,000; to increase funding for medical support and compliance by $69,691,000; to increase funding for medical facilities by $105,132,000; to increase funding for Departmental Administration by $10 million; to increase funding for information technology systems by $95 million; increase funding for major project construction by $582 million; and to strike Secs. 233, 238 and 240, each of which provides for a recession of funds.

United States · United States Congress

Resolution· HRESH.Res. 1301 (119th)referred

Supporting the designation of May 29, 2026, as "Mental Health Awareness in Agriculture Day" to raise awareness around mental health in the agricultural industry and workforce and to continue to reduce stigma associated with mental illness.

United States · United States Congress · 19 May 2026

This resolution supports the designation of Mental Health Awareness in Agriculture Day to raise awareness around mental health in the agricultural industry and reduce the stigma associated with mental illness.

Bill· HRH.R. 8205 (119th)open

Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026

United States · United States Congress · 6 April 2026

Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026 This bill reauthorizes through FY2031 and revises programs that support research and development of drugs and other therapies to address amyotrophic lateral sclerosis (also known as ALS or Lou Gehrig's disease) and other neurodegenerative diseases. The bill reauthorizes grants from the National Institutes of Health (NIH) for scientific research on investigational drugs to prevent or treat ALS for individuals not otherwise eligible for clinical trials, grants from the Food and Drug Administration (FDA) for research and development of therapies to prevent and treat ALS and other neurodegenerative diseases, and a Public-Private Partnership including the FDA and NIH that supports development and regulatory review of treatments for neurodegenerative diseases.  Also, the NIH, in considering renewal of its grants, must assess available information on the safety and efficacy of the investigational drugs. It must also require grantees to promptly report serious and unexpected adverse events associated with their investigational drugs. Additionally, the FDA must publish a plan describing actions it will take over a five-year period to foster development of safe and effective drugs, and facilitate access to investigational drugs, that treat ALS and other rare neurodegenerative diseases. The FDA must also publish a report describing the actions it has taken under the plan.